Dx & Vx Co

Dx & Vx Co OCF Margin

The Operating Cash Flow Margin of Dx & Vx Co (180400.KQ) as of Nov 3, 2026 is -64.23 %. In the previous year, Operating Cash Flow Margin was -58.99 % — a change of 8.87% (lower).

OCF Margin

-64.23 %

YoY

8.87%

Last updated:

Operating Cash Flow Margin of Dx & Vx Co is 2025 -64.23 % . Operating Cash Flow Margin of Dx & Vx Co was 2024 -58.99 % . It decreases by 8.87% lower compared to the previous year.

The Dx & Vx Co OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
-65.81 KRW
Jan 1, 2019
-72.08 KRW
Jan 1, 2020
-89.20 KRW
Jan 1, 2021
-36.94 KRW
Jan 1, 2022
2.69 KRW
Jan 1, 2023
-29.24 KRW
Jan 1, 2024
-58.99 KRW
Jan 1, 2025
-64.23 KRW
The Dx & Vx Co OCF Margin history
YEAROCF MarginYoY
-64.23 %+8.87%
-58.99 %+101.72%
-29.24 %-1,187.41%
2.69 %-107.28%
-36.94 %-58.58%
-89.20 %+23.74%
-72.08 %+9.53%
-65.81 %+43.92%
-45.73 %+55.09%
-29.49 %+88.85%
-15.61 %-193.44%
16.71 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dx & Vx Co Stock analysis

What does Dx & Vx Co do? Dx & Vx Co., Ltd. generates revenue through the Molecular Diagnosis Business segment, which focuses on manufacturing and selling DNA chips, PCR chips, and related diagnostic reagents for molecular diagnosis. The company also produces enzymes and experimental reagents for biological research, targeting laboratories and healthcare facilities that require molecular diagnostic tools. Its products are sold to institutions involved in medical testing and research, leveraging the demand for advanced diagnostic solutions in healthcare. The company's revenue streams are derived from direct sales of these specialized products to the healthcare and research sectors. Dx & Vx Co., Ltd. operates within the molecular diagnostics market, offering DNA chips, PCR chips, and diagnostic reagents as core products. The company's focus on manufacturing and selling these items positions it as a provider of essential tools for molecular biology applications. Sales are directed toward laboratories and healthcare providers seeking to enhance their diagnostic capabilities through cutting-edge technology. The business model relies on consistent demand for molecular diagnostic equipment and reagents within the medical and research industries. Dx & Vx Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dx & Vx Co stock

Operating Cash Flow Margin of Dx & Vx Co is -64.23 % in 2025.

Operating Cash Flow Margin of Dx & Vx Co changed from -58.99 % to -64.23 %, representing a 8.87% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Dx & Vx Co since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Dx & Vx Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Dx & Vx Co

All Key Metrics — Dx & Vx Co